Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02 · 8-K

ChronoScale Holdings Corporation

CHRNNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Board Resignation of and Release Agreement with Mr. Davis As previously announced, on September 30, 2026, ChronoScale Holdings Corporation, a Nevada corporation (the “Company”) completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc. (“Ekso”).…

Filed Oct 6, 2026Accepted Oct 6, 2026, 5:20 PM EDTCIK 1549084Accession 0001493152-26-046010
Share

Company context

Current securities

Historical securities (1)

Recent company filings

  1. DEFA14A filingOct 16, 2026
  2. Results of Operations and Financial ConditionOct 15, 2026
  3. 10-Q filingOct 14, 2026
  4. EFFECT filingOct 9, 2026
  5. S-8 POS filingOct 6, 2026

Registered securities in this filing

CHRONOSCALE HOLDINGS CORPORATION · 8-K · Filed 2026-10-06

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
CHRN
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-10-02

Dimensions: Not supplied

Accession 000149315226046010 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Board Resignation of and Release Agreement with Mr. Davis As previously announced, on September 30, 2026, ChronoScale Holdings Corporation, a Nevada corporation (the “Company”) completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc. (“Ekso”). In connection with the sale of Ekso (the “Transaction”), Scott Davis, a member of the Board of Directors of the Company (the “Board”) and Chief Executive Officer (“CEO”) of Ekso, resigned from his position as a member of the Board, effective as of October 3, 2026. There were no disagreements between the Company and Mr. Davis that led to his decision to resign. Also, in connection with the consummation of the Transaction, on October 2, 2026, the Company (i) granted an award of 51,626 restricted stock units (“RSUs”) to Mr. Davis, which fully vested on the grant date, and (ii) entered into a Release Agreement with Mr. Davis (the “Release Agreement”). Pursuant to the Release Agreement, Mr. Davis is entitled to receive a lump sum cash payment of $709,500, less applicable withholdings and deductions (the “Release Payment”). The Release Payment is payable within 30 days of the execution of the Release Agreement. The Release Payment is subject to Mr. Davis’s compliance with the Release Agreement and his continuing restrictive covenants. In exchange for the Release Payment, Mr. Davis has agreed to a general release of claims against the Company and its past, present, and future parent organizations, subsidiaries, and affiliated entities. The Release Agreement also provides that it does not amend, alter, or modify the terms and conditions of the Phantom Performance-Based Restricted Stock Unit Agreement between ChronoScale Intermediate LLC, a wholly owned subsidiary of the Company (“ChronoScale Intermediate”) and Mr. Davis dated November 5, 2025, as described in the Company’s Current Report on Form 8-K filed with the SEC on November 7, 2025. The Release Agreement was entered into in lieu of, and in full satisfaction of, any payment or benefit that Mr. Davis may otherwise have been entitled to receive pursuant to that certain Change in Control and Severance Agreement between ChronoScale Intermediate and Mr. Davis, dated November 5, 2025, filed with the SEC as Exhibit 10.2 to the Company’s Current Report on Form 8-K on November 7, 2025.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.